Provided are a recombinant respiratory syncytial virus (RSV) fusion (F) protein, and a fusion protein, vaccine, immunogenic composition, kit and pharmaceutical composition comprising same. Further provided is a use of the recombinant RSV F protein, fusion protein, vaccine, immunogenic composition, kit and pharmaceutical composition in preventing and/or treating RSV infection or diseases and/or symptoms caused by RSV infection.
The present invention relates to the field of immunology and the field of molecular virology, in particular to the field of prevention and treatment of varicella-zoster viruses. Specifically, the present invention relates to a truncated varicella-zoster virus gE protein (or a variant thereof) capable of be soluble expression in an Escherichia coli expression system, and use thereof in preventing and/or treating varicella-zoster virus infections.
BEIJING TIANTAN HOSPITAL, CAPITAL MEDICAL UNIVERSITY (China)
Inventor
Wang, Haihong
Zhang, Guojun
Tong, Xunzhang
Ke, Qishen
Zou, Mengwen
Shi, Yijun
Jiang, Wencan
Li, Xiaotong
Ding, Yaowei
Xu, Ting
Li, Xiangyun
Xiong, Junhui
Sun, Xudong
Abstract
The present application belongs to the technical field of biomedicine. More specifically, the present application relates to a kit for detecting whether a subject suffers from multiple sclerosis (MS). Furthermore, the present application relates to a kit capable of being used for discriminating MS and neuromyelitis optica spectrum disorders (NMOSD). Further, the present application also relates to a method for screening a reagent or a reagent combination which can be used for detecting whether a subject suffers from MS and can discriminate NMOSD and MS.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
4.
IMMUNE-ENHANCING ALUMINUM EMULSION, AND PREPARATION METHOD THEREFOR AND USE THEREOF
An immune-enhancing aluminum emulsion, and a preparation method therefor and a use thereof. Specifically provided are an oil-in-water emulsion containing an inorganic salt and a preparation method for the oil-in-water emulsion. Also provided are a vaccine adjuvant comprising the oil-in-water emulsion, a vaccine composition and a pharmaceutical composition. Also provided is a use of the oil-in-water emulsion as a vaccine adjuvant.
A method for diagnosing rheumatoid arthritis on the basis of the level of an anti-citrullinated SETDB1 antibody, and a kit for use in the method. Provided are a polypeptide for the above-mentioned diagnosis of the level of an anti-citrullinated SETDB1 antibody, and the use thereof in the diagnosis of rheumatoid arthritis.
C07K 4/12 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof from animalsPeptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof from humans
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
6.
RECOMBINANT THYROID-STIMULATING HORMONE RECEPTOR PROTEIN, PREPARATION METHOD AND APPLICATION THEREOF
The present invention provides a recombinant thyroid stimulating hormone receptor protein, a preparation method therefor and an application thereof. The recombinant thyroid stimulating hormone receptor protein comprises a TSHR protein extracellular segment and a TSHR protein intracellular segment. The C-terminus of the TSHR protein extracellular segment is linked to the N-terminus of the TSHR protein intracellular segment. The protein achieves extracellular soluble expression, and is high in purity, high in activity and good in stability.
The present disclosure relates to a microfluidic chip and a microfluidic chip detection system. The microfluidic chip including: a storage member provided with a groove therein, at least two storage chambers being disposed around the groove; a base disposed at one end of the storage member away from the groove, a reaction chamber being disposed on the base; and a valve disposed in the groove, the valve being configured to operatively communicate any one of the at least two storage chambers with the reaction chamber. The present disclosure can lead the solution in any storage chamber to the reaction chamber or lead the solution in the reaction chamber to any storage chamber by operating the valve, so that the solution transfer is realized, the structure is simple and compact, the length of the flow channels can be greatly shortened, and the detection efficiency is improved.
The present invention provides fusion proteins of gE and gI (or variants thereof) that can be used for preventing or treating varicella-zoster virus infection, and use of such fusion proteins (or the variants thereof).
Provided are a fusion protein and a composition, a kit, a granulated antigen, a vaccine, and a pharmaceutical composition comprising same. The present invention also relates to use of the fusion protein and the composition, the kit, and the granulated antigen comprising same in the preparation of a pharmaceutical composition or a vaccine. The granulated antigen is particularly suitable for the production and vaccination of a vaccine and has advantages in the prevention and/or treatment of viral infections.
Described are methods for the preparation of a HPV vaccine composition by, for example (i) adsorbing one or more HPV antigen(s) on a metallic salt and, then (ii) adding a non adsorbed glycolipid based TLR4 ligand to the mixture obtained in (i). Resulting HPV vaccine compositions and uses thereof are also described.
Provided are a fusion protein, and a nucleic acid molecule comprising a nucleotide sequence encoding the fusion protein. The present invention also relates to a vaccine comprising the fusion protein or the nucleic acid molecule. Furthermore, the present invention also relates to a method for preventing and/or treating RSV infections or diseases and/or symptoms caused by RSV infections by means of using the fusion protein, the nucleic acid molecule and the vaccine.
BEIJING TIANTAN HOSPITAL, CAPITAL MEDICAL UNIVERSITY (China)
Inventor
Wang, Haihong
Zhang, Guojun
Tong, Xunzhang
Ke, Qishen
Zou, Mengwen
Shi, Yijun
Jiang, Wencan
Li, Xiaotong
Ding, Yaowei
Xu, Ting
Li, Xiangyun
Xiong, Junhui
Sun, Xudong
Abstract
The present application belongs to the technical field of biomedicine. More specifically, the present application relates to a kit for detecting whether a subject suffers from multiple sclerosis (MS). Furthermore, the present application relates to a kit capable of being used for discriminating MS and neuromyelitis optica spectrum disorders (NMOSD). Further, the present application also relates to a method for screening a reagent or a reagent combination which can be used for detecting whether a subject suffers from MS and can discriminate NMOSD and MS.
Provided are a newly designed HIV-1 Env trimer protein, and an HIV-1 pseudovirus and virus expressing the Env trimer protein, and the use thereof for the prevention and/or treatment of HIV infection.
An adjuvant containing zinc aluminum risedronate, an immunogenic composition comprising the adjuvant and an immunogen, and uses of the adjuvant and the immunogenic composition.
Provided are a method for diagnosing nasopharyngeal carcinoma on the basis of the anti-EB virus (EBV) antibody level and a kit used for the method. Also provided are a polypeptide encoded by a BNLF2b gene in EB virus used for the above-mentioned diagnosis and the use thereof for diagnosing nasopharyngeal carcinoma.
The present invention relates to the field of immunology and the field of molecular virology, in particular to the field of prevention and treatment of varicella-zoster viruses. Specifically, the present invention relates to a truncated varicella-zoster virus gE protein (or a variant thereof) capable of soluble expression in an Escherichia coli expression system, and use thereof in preventing and/or treating varicella-zoster virus infections.
A thyroid stimulating hormone receptor complex, a kit, a preparation method and the use, the thyroid stimulating hormone receptor complex comprising: a thyroid stimulating hormone receptor, a thyroid stimulating hormone receptor C-terminal monoclonal antibody and magnetic particles, the thyroid stimulating hormone receptor being connected to the magnetic particles by means of the thyroid stimulating hormone receptor C-terminal monoclonal antibody. The thyroid stimulating hormone receptor complex and the test kit have good stability, and relatively high sensitivity and specificity.
The present invention belongs to the field of biomedicine, and relates to a SARS-CoV-2 spike protein variant, a pharmaceutical composition and the use thereof. Specifically, the present invention relates to an isolated polypeptide having an amino acid sequence as shown in any one of SEQ ID NOs: 1-27. The polypeptide of the present invention can simulate broad-spectrum neutralizing antibodies against existing different COVID-19 variant strains, and has a good protection effect on both a SARS-CoV-2 prototype strain and variant strain.
A microfluidic chip and a microfluidic chip testing system. The microfluidic chip comprises: a storage member (1) on which a recess (11) is provided, at least two storage chambers (12) being provided around the recess (11); a base (2), disposed at an end of the storage member (1) facing away from the recess (11), a reaction chamber (21) being provided on the base; and a valve (3) disposed in the recess (11), the valve (3) being configured to operably put any one of the at least two storage chambers (12) in communication with the reaction chamber (21). By means of operating the valve (3), a solution in any storage chamber (12) can be guided into the reaction chamber (21), or a solution in the reaction chamber (21) can be guided to any storage chamber (12), thereby implementing solution transfer.
The present invention provides a recombinant thyroid stimulating hormone receptor protein, a preparation method therefor and an application thereof. The recombinant thyroid stimulating hormone receptor protein comprises a TSHR protein extracellular segment and a TSHR protein intracellular segment. The C-terminus of the TSHR protein extracellular segment is linked to the N-terminus of the TSHR protein intracellular segment. The protein achieves extracellular soluble expression, and is high in purity, high in activity and good in stability.
In the field of Hepatitis B virus (HBV) detection, disclosed are a method for detecting HBcAg by means of using a double antibody sandwich method, and an antibody and kit for detecting HBcAg; also included is a monoclonal antibody that can be used in the immunological detection of HBcAg in a tissue or cell sample.
A multimerization delivery system that can be used to deliver a cargo molecule intracellularly. The multimerization delivery system can achieve high-efficiency endocytosis of a cargo molecule and high-efficiency release thereof from an endocytic vesicle, significantly improving the cytoplasmic delivery efficiency of the cargo molecule. Once the cargo molecule is available in the cytoplasm, the cargo molecule can play any role related thereto. The multimerization delivery system provides an effective means for affecting the biological mechanisms and pathways of cells, and can be used in various fields such as research, treatment, and diagnosis.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
Described are methods for the preparation of a HPV vaccine composition by, for example (i) adsorbing one or more HPV antigen(s) on a metallic salt and, then (ii) adding a non adsorbed glycolipid based TLR4 ligand to the mixture obtained in (i). Resulting HPV vaccine compositions and uses thereof are also described.
The present invention pertains to the field of pharmaceutical technology. Specifically, the present invention relates to a zinc risedronate micro/nano adjuvant with sustained-release function formed by mineralization of zinc ions and risedronic acid as main components and its use as a vaccine adjuvant. The present invention also relates to a method for preparing zinc risedronate micro/nano adjuvant. The present invention also relates to a chemical composition, vaccine adjuvant and vaccine composition comprising zinc risedronate micro/nano adjuvant. The present invention also relates to a use of zinc risedronate micro/nano adjuvant as a vaccine adjuvant.
Disclosed is a zinc zoledronate micro-nanoparticle adjuvant, which contains zinc and zoledronic acid and optionally contains a phosphate and aluminum. The preparation method therefor comprises performing mixed precipitation on a soluble salt solution containing zinc ions, zoledronic acid, and sodium hydroxide. The adjuvant can be used to prepare vaccines, etc.
Provided are a newly designed HIV-1 Env trimer protein, and an HIV-1 pseudovirus and euvirus expressing the Env trimer protein, and the use thereof for the prevention and/or treatment of HIV infection.
An adjuvant containing zinc aluminum risedronate, an immunogenic composition comprising the adjuvant and an immunogen, and uses of the adjuvant and the immunogenic composition.
Provided are a method for inactivating respiratory syncytial virus (RSV) and stabilizing pre-F protein in RSV and inactivated RSV virus obtained thereby. Also provided are a vaccine comprising the inactivated RSV virus and a use of the vaccine in preventing or treating RSV infection or a disease related thereto.
Provided are a mutated HPV51 L1 protein or a variant thereof, a coding sequence thereof, a preparation method therefor, and a virus-like particle containing same, wherein the protein or the variant and the virus-like particle thereof are capable of inducing neutralizing antibodies against at least two types of HPV (for example, HPV51 and HPV69, or HPV51, HPV69 and HPV26). Also provided is the use of the above-mentioned protein and the virus-like particle for preparing a pharmaceutical composition or a vaccine, wherein the pharmaceutical composition or the vaccine can be used to prevent infections of the at least two types of HPV and diseases caused by the infections, such as cervical cancer and condyloma acuminatum.
The invention provides a kit for full-range detection of C-reactive protein based on chemiluminescence immunoassay and a method for full-range detection of C-reactive protein. The kit comprises an R1 reagent, an M reagent, an R2 reagent, a pre-excitation solution and an excitation solution. The R1 reagent, that is a sample treatment solution, is a 0.5M citric acid solution (pH 3.0-3.5, which is adjusted by disodium hydrogen phosphate dodecahydrate). The present invention also provides a kit for full-range detection of C-reactive protein, which comprises a flat-bottomed plate-type chemiluminescence plate coated with a first antibody, a sample treatment solution, a second antibody labeled with horseradish peroxidase (HRP) or alkaline phosphatase (AP), a color developing solution. The invention also provides a method for full-range detection of C-reactive protein using the kit. Both the first antibody and the second antibody are monoclonal antibodies that can specifically react with C-reactive protein.
The invention relates to a mutated HPV66 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (e.g. HPV66 and HPV56, or HPV66, HPV56 and HPV53), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.
The present invention relates to a mutated HPV18 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (for example, HPV18 and HPV45, or HPV18, HPV45 and HPV59), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.
In the field of Hepatitis B virus (HBV) detection, disclosed are a method for detecting HBcAg by means of using a double antibody sandwich method, and an antibody and kit for detecting HBcAg; also included is a monoclonal antibody that can be used in the immunological detection of HBcAg in a tissue or cell sample.
A multimerization delivery system that can be used to deliver a cargo molecule intracellularly. The multimerization delivery system can achieve high-efficiency endocytosis of a cargo molecule and high-efficiency release thereof from an endocytic vesicle, significantly improving the cytoplasmic delivery efficiency of the cargo molecule. Once the cargo molecule is available in the cytoplasm, the cargo molecule can play any role related thereto. The multimerization delivery system provides an effective means for affecting the biological mechanisms and pathways of cells, and can be used in various fields such as research, treatment, and diagnosis.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 9/00 - Medicinal preparations characterised by special physical form
37.
POLYPEPTIDE ENCODED BY BNLF2B GENE IN EB VIRUS AND DETECTION USE THEREOF
Provided are a method for diagnosing nasopharyngeal carcinoma on the basis of the anti-EB virus (EBV) antibody level and a kit used for the method. Also provided are a polypeptide encoded by a BNLF2b gene in EB virus used for the above-mentioned diagnosis and the use thereof for diagnosing nasopharyngeal carcinoma.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
38.
Mutant of L1 protein of human papillomavirus type 39
The invention relates to a mutated HPV39 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (e.g. HPV39 and HPV68, or HPV39, HPV68 and HPV70), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.
A kit for quantitatively detecting HBsAg and a method for quantitatively detecting an HBsAg content in a sample containing HBsAg. The kit comprises a first antibody specifically binding to HBsAg and a reagent composition. The reagent composition comprises tris(2-carboxyethyl)phosphine hydrochloride (TCEP) and urea.
A fusion protein and a complex containing same, capable of being used for the intracellular delivery of cargo molecules. The fusion protein and complex can implement the efficient release of cargo molecules from endocytic vesicles, thereby significantly improving the cytoplasmic delivery efficiency of the cargo molecules. One cargo molecules can be obtained in cytoplasms, they can exert any function related thereto. The fusion protein and complex provide effective means for affecting biological mechanisms and pathways of cells, and can be used in various fields such as research, treatment, and diagnosis.
A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
Provided are a mutated HPV16 L1 protein (or a variant thereof), a sequence encoding the same and a method for preparing the same, as well as a virus-like particle comprising the same. The protein (or variant thereof) and the virus-like particle are capable of inducing neutralizing antibodies against at least two types of HPV (e.g., HPV16 and HPV35, or HPV16, HPV35, and HPV31), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. Also provided are a use of the above protein and virus-like particle in the manufacture of a pharmaceutical composition or vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.
The present invention falls within the technical field of medicine. In particular, the present invention relates to a risedronate zinc micronano-adjuvant which has a slow-release function and is formed by mineralizing the major components, zinc ions and risedronic acid, and the use of same as a vaccine adjuvant. The present invention also relates to a method for preparing the risedronate zinc micronano-adjuvant. The present invention also relates to a chemical composition, a vaccine adjuvant and a vaccine composition containing the risedronate zinc micronano-adjuvant. Furthermore, the present invention relates to the use of the risedronate zinc micronano-adjuvant as a vaccine adjuvant.
Disclosed is a zinc zoledronate micro-nanoparticle adjuvant, which contains zinc and zoledronic acid and optionally contains a phosphate and aluminum. The preparation method therefor comprises performing mixed precipitation on a soluble salt solution containing zinc ions, zoledronic acid, and sodium hydroxide. The adjuvant can be used to prepare vaccines, etc.
The invention relates to a truncated rotavirus VP4 protein, a sequence encoding the same, a method for preparing the same, and a pharmaceutical composition and a vaccine comprising the protein, wherein the protein, the pharmaceutical composition and the vaccine are useful for preventing, alleviating or treating rotavirus infection and a disease caused by rotavirus infection, such as rotavirus gastroenteritis and diarrhea. The invention further relates to use of the protein in the manufacture of a pharmaceutical composition or a vaccine for preventing, alleviating or treating rotavirus infection and a disease caused by rotavirus infection, such as rotavirus gastroenteritis and diarrhea.
Provided are a mutated HPV58 L1 protein or a variant thereof, a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein or a variant thereof and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types, and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.
Provided are a mutated HPV51 L1 protein or a variant thereof, a coding sequence thereof, a preparation method therefor, and a virus-like particle containing same, wherein the protein or the variant and the virus-like particle thereof are capable of inducing neutralizing antibodies against at least two types of HPV (for example, HPV51 and HPV69, or HPV51, HPV69 and HPV26). Also provided is the use of the above-mentioned protein and the virus-like particle for preparing a pharmaceutical composition or a vaccine, wherein the pharmaceutical composition or the vaccine can be used to prevent infections of the at least two types of HPV and diseases caused by the infections, such as cervical cancer and Condyloma acuminatum.
Provided are a method for inactivating respiratory syncytial virus (RSV) and stabilizing pre-F protein in RSV and inactivated RSV virus obtained thereby. Also provided are a vaccine comprising the inactivated RSV virus and a use of the vaccine in preventing or treating RSV infection or a disease related thereto.
Provided in the present invention are a kit for performing full course detection of C-reactive protein on the basis of chemiluminescence immunoassay and a method for performing full course detection of the C-reactive protein. The kit comprises an R1 reagent, an M reagent, an R2 reagent, a pre-excitation solution, and an excitation solution. The R1 reagent, i.e. a sample treatment solution, is a 0.5M citric acid solution (pH 3.0-3.5, which is adjusted using disodium hydrogen phosphate dodecahydrate). Also provided in the present invention is a kit for performing full course detection of C-reactive protein, comprising a flat-bottomed chemiluminescence plate coated by a first antibody, the sample treatment solution, a horseradish peroxidase (HRP) or alkaline phosphatase (AP) labeled secondary antibody, and a color developing solution. Also provided in the present invention is a method for use in performing full course detection of C-reactive protein using the foregoing kit. Both the first antibody and the second antibody are monoclonal antibodies that may specifically react with the C-reactive protein.
The present invention relates to a mutated HPV 18 L1 protein (or a variant thereof), a coding sequence thereof and a preparation method therefor, as well as a virus-like particle containing same; the protein (or a variant thereof) and the virus-like particle are capable of inducing a neutralizing antibody against at least two types of HPV (such as HPV 18 and HPV 45, or HPV 18, HPV 45, and HPV 59), and thus may be used for preventing infection from at least two types of HPV as well as diseases caused by the infection, such as cervical cancer and condyloma acuminata. The present invention also relates to a use of the described protein and virus-like particle in the preparation of a pharmaceutical composition or vaccine, wherein the pharmaceutical composition or vaccine may be used to prevent infection from at least two types of HPV as well as diseases caused by the infection, such as cervical cancer and condyloma acuminata.
Involved are a mutated HPV39 L1 protein (or a variant thereof), the coding sequence thereof and a preparation method therefor, as well as a virus-like particle comprising same. The protein (or a variant thereof) and the virus-like particle are capable of inducing a neutralizing antibody combating at least two types of HPVs (such as HPV39 and HPV68, or HPV39, HPV68 and HPV70), and thus can be used for preventing infections of the at least two types of HPVs and diseases caused by the infections, such as cervical cancer and condylomata acuminata. Also involved are the uses of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine. The pharmaceutical composition or vaccine can be used for preventing infections of the at least two types of HPVs and diseases caused by the infections, such as cervical cancer and condylomata acuminata.
The present invention relates to a mutated HPV 66 L1 protein (or a mutant thereof), a coding sequence thereof and a preparation method therefor, and a virus-like particle comprising same. The protein (or the mutant thereof) and the virus-like particle can induce a neutralizing antibody against at least two HPV types (for example, HPV 66 and HPV 56, or HPV 66, HPV 56, and HPV 53), and thus can be used for preventing infections with the at least two HPV types and diseases caused by the infections, such as cervical cancer and condylomata acuminata. The present invention also relates to applications of the protein and of the virus-like particle in preparation of a pharmaceutical composition or vaccine. The pharmaceutical composition or vaccine can be used for preventing infections with the at least two HPV types and diseases caused by the infections, such as cervical cancer and condylomata acuminata.
A kit for quantitative detecting HBsAg and a method for quantitative detecting an HBsAg content in a sample containing HBsAg. The kit comprises a first antibody specifically binding to HBsAg and a reagent composition. The reagent composition comprises tris(2-carboxyethyl)phosphine hydrochloride (TCEP) and urea.
Disclosed are a mutated HPV11 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (e.g. HPV11 and HPV6), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. Also disclosed is use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.
Disclosed are a reaction tube for nucleic acid amplification capable of controlling a liquid circulation path, a reaction apparatus for nucleic acid amplification comprising the reaction tube, and a method for amplifying nucleic acid comprising a step of using the reaction tube. Also disclosed are a kit comprising the reaction tube, and use of the reaction tube in preparation of a kit.
Provided is a mutated HPV16 L1 protein (or a mutant thereof), the coding sequence and a preparation method for same, and a virus-like particle comprising same. The protein (or the mutant thereof) and the virus-like particle are capable of inducing a neutralizing antibody against at least two types of HPV (for example, HPV16 and HPV35 or HPV16, HPV35 and HPV31), thus being applicable in preventing infections by the at least two types of HPV and diseases caused by the infections, such as cervical cancer and condylomata acuminata. Also provided are uses of the protein and of the virus-like particle in preparing a pharmaceutical composition or vaccine. The pharmaceutical composition or vaccine is applicable in preventing infections by the at least two types of HPV and diseases caused by the infections, such as cervical cancer and condylomata acuminata.
The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.
Provided are a method for inactivating respiratory syncytial virus (RSV) and stabilizing RSV pre-F protein, and inactivated RSV obtained by the method. Also provided are a method for preparing an immunogenic composition containing a pre-F protein, and an immunogenic composition obtained by the method. Also provided are applications of the inactivated RSV and the immunogenic composition.
The invention relates to a truncated rotavirus VP4 protein, a sequence encoding the same, a method for preparing the same, and a pharmaceutical composition and a vaccine comprising the protein, wherein the protein, the pharmaceutical composition and the vaccine are useful for preventing, alleviating or treating rotavirus infection and a disease caused by rotavirus infection, such as rotavirus gastroenteritis and diarrhea. The invention further relates to use of the protein in the manufacture of a pharmaceutical composition or a vaccine for preventing, alleviating or treating rotavirus infection and a disease caused by rotavirus infection, such as rotavirus gastroenteritis and diarrhea.
Provided are a mutated HPV58 L1 protein or a variant thereof, a coding sequence thereof, a preparation method, and a virus-like particle comprising the protein or the variant thereof, wherein the protein or the variant thereof and the virus-like particle are capable of inducing neutralization antibodies against at least two types of HPV, and can then be used to prevent infection with at least two types of HPV and diseases caused by the infection.
Disclosed are a mutated HPV11 L1 protein (or a variant thereof), a coding sequence and a preparation method thereof, and a virus-like particle comprising same, wherein the protein (or a variant thereof) and the virus-like particle are capable of inducing neutralization antibodies against at least two types of HPV (for example, HPV11 and HPV6), and can thus be used to prevent infection with at least two types of HPV and diseases caused by the infection, such as cervical cancer and condyloma acuminata. Also disclosed is a use of the above-mentioned protein and the virus-like particle for preparing a pharmaceutical composition or vaccine. The pharmaceutical composition or vaccine can be used to prevent infection with at least two types of HPV and diseases caused by the infection, such as cervical cancer and condyloma acuminata.
The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.
Provided is a nucleic acid molecular, comprising a nucleotide sequence coding a polypeptide carrier. Also provided are a recombinant protein comprising the polypeptide carrier and a target polypeptide, and uses of the nucleic acid molecular and the recombinant protein. Also provided is a vaccine or pharmaceutical composition that can be used for prevention, alleviation, or treatment of HBV infections or HBV infection-related diseases (for example, hepatitis B), the composition comprising the polypeptide carrier and a recombinant protein from an HBV epitope.
Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.
Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.
Disclosed is a nucleic acid amplification reaction tube capable of controlling a liquid circulation path and comprising a nucleic acid amplification reaction device of the reaction tube, and a method of amplifying the nucleic acid using the reaction tube. Also disclosed are a reagent container including the reaction tube and use of the reaction tube for preparing the reagent container.
Provided are an N-terminal truncated L1 protein of the Human Papillomavirus Type 58, a coding sequence and preparation method thereof, and a virus-like particle comprising the protein. Uses of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine are further provided. The pharmaceutical composition or vaccine is used for prevention of HPV infection and a disease caused by HPV infection.
The invention relates to a method for preparing double-layered virus-like particles of rotavirus in vitro. The method comprises the following steps: purifying rotavirus VP6 proteins from a lysis supernatant, and in vitro assembling double-layered virus-like particles consisting of VP2 proteins and VP6 proteins, wherein the proteins and the virus-like particles can be used for preventing or reducing the clinical symptoms caused by rotavirus infection.
C12N 7/04 - Inactivation or attenuationProducing viral sub-units
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 39/00 - Medicinal preparations containing antigens or antibodies
69.
Anti-HBc quantitative detection method and uses thereof in monitoring and controlling disease progression of chronic hepatitis B patient and in predicting therapeutic effect
The present invention relates to a method for quantitative detection of anti-HBc and its use in monitoring disease progression of chronic hepatitis B patients and predicting therapeutic effects. By quantitative detection of antibodies against hepatitis B core protein (Anti-HBc), it is able to monitor disease progression of chronic hepatitis B patients, effectively predict therapeutic effects in chronic hepatitis B patients who accept a therapy against hepatitis B virus (especially, a therapy based on interferon and a therapy based on nucleoside/nucleotide analog anti-HBV drug), and thus guide the patients to reasonably choose drugs.
The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the truncated L1 protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
XIAMEN INNOVAX BIOTECH CO., LTD. (China)
Inventor
Zheng, Zizheng
Mclellan, Jason S.
Chen, Man
Zhao, Min
Huang, Liangmin
Graham, Barney S.
Xia, Ningshao
Abstract
Provided are an epitope peptide which can be used in the prevention of respiratory syncytial virus infections, or variants thereof and a recombinant protein comprising the epitope peptide or variants thereof with a carrier protein, and uses thereof. Also provided in the present invention are an antibody against these epitope peptides and cell strains generating the antibody, and uses thereof. Furthermore, also provided in the present invention are a vaccine comprising the recombinant protein or a pharmaceutical composition comprising the antibody, and the vaccine or pharmaceutical composition can be used for preventing symptoms related to respiratory syncytial virus infections.
The present invention relates to a truncated L1 protein of Human Papillomavirus (HPV) Type 33, a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein and the virus-like particle are useful for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer. The invention also relates to the use of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer.
Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.
The present invention relates to an in vitro preparation method of rotavirus double-layer virus-like particles, comprising: purifying a rotavirus VP6 protein in a cracked supernatant, and performing in vitro assembly of double-layer virus-like particles formed by a VP2 protein and the VP6 protein. The proteins and the virus-like particles can be used to prevent or alleviate clinical symptoms caused by infection of the rotavirus.
The present invention relates to epitope peptides (or mutants thereof) for treating hepatitis B virus infection, recombinant proteins comprising such epitope peptides (or mutants thereof) and carrier proteins, and uses of such epitope peptides (or mutants thereof) and recombinant proteins. The present invention also relates to antibodies against such epitope peptides, cell lines producing said antibodies, and uses thereof. Furthermore, the present invention relates to vaccines or pharmaceutical compositions for treating or alleviating one or more symptoms relating to hepatitis B virus infection, which respectively comprise recombinant proteins or antibodies in the present invention.
C07K 14/02 - Hepadnaviridae, e.g. hepatitis B virus
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are an N-terminal truncated L1 protein of the Human Papillomavirus Type 58, a coding sequence and preparation method thereof, and a virus-like particle comprising the protein. Uses of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine are further provided. The pharmaceutical composition or vaccine is used for prevention of HPV infection and a disease caused by HPV infection.
E. coli expression system. The truncated HPV52 L1 protein and an assembled VLP can be used to prevent an HPV52 infection and a disease caused by HPV52 infection, such as cervical cancer.
C07K 14/025 - Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
78.
ANTI-HBC QUANTITATIVE DETECTION METHOD AND USES THEREOF IN MONITORING AND CONTROLLING DISEASE PROGRESSION OF CHRONIC HEPATITIS B PATIENT AND IN PREDICTING THERAPEUTIC EFFECT
Disclosed in the present invention are an antibodies against hepatitis B core protein (Anti-HBc) quantitative detection method and the uses thereof in monitoring and controlling disease progression of a chronic hepatitis B patient and in predicting therapeutic effect. Anti-HBc are quantitatively detected, so that disease progression of a chronic hepatitis B patient is monitored and controlled, and the therapeutic effect on a chronic hepatitis B patient under anti-hepatitis B virus (HBV) treatment (especially, under treatment based on interferon and under treatment through anti-HBV medicine based on nucleoside or nucleotide analogues) is effectively predicted, thereby guiding the patient to reasonably select medicine.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
79.
METHOD AND DEVICE FOR PERFORMING POLYMERASE CHAIN REACTION UNDER CONSTANT HEAT RESERVOIR
Provided is a method and device for performing a polymerase chain reaction under a constant heat reservoir, wherein the method is a method based on the Rayleigh-Benard principle, whereby heat is provided to or removed from specific regions of reaction tubes to establish a bottom-up temperature gradient for the reagents in the reaction tubes, and convection occurs spontaneously due to the uneven heating of the reaction reagents; thus corresponding PCR amplification occurs when fluids flow through the different temperature regions. Also provided are a reaction to realize the method and a device for real-time fluorescent detection.
Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
C12N 15/62 - DNA sequences coding for fusion proteins
Provided are a truncated human papillomavirus type 33 protein L1, an encoding sequence and a preparation method thereof, a virus-like particle consisting of the protein, a vaccine comprising the virus-like particle and a use thereof in preventing HPV infection and related diseases.
Provided are an anti-CD4 protein monoclonal antibody, active fragments and uses thereof. The antibody of the present invention can block the binding of the human immunodeficiency virus and human CD4 protein for invasion into cells. The antibody of the present invention can be used for detecting, diagnosing, preventing and treating diseases of which target cells are CD4 cells, especially AIDS caused by the human immunodeficiency virus (HIV). Further provided are corresponding hybridoma cell lines, isolated nucleic acids molecule and oligopeptides, as well as pharmaceutical compositions and kits comprising the monoclonal antibody.
C07K 16/06 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies from serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are an N-terminal truncated human papillomavirus type 58 L1 protein, a coding sequence and preparation method thereof, and virus-like particles comprising the protein. Uses of the protein and the virus-like particles in preparation of a pharmaceutical composition or a vaccine are further provided. The pharmaceutical composition or vaccine is used for prevention of HPV infection and diseases caused by HPV infection.
Provided is a truncated L1 protein of human papillomavirus (HPV) type 52 which, compared to a wild-type HPV52 L1 protein, is truncated by 27 – 42 amino acids at the N-terminal. Also provided are a coding sequence of the truncated HPV52 L1 protein, a virus-like particle (VLP) comprising the protein, and a method of preparing the protein and the VLP using an Escherichia coli expression system. The truncated HPV52 L1 protein and an assembled VLP can be used to prevent an HPV52 infection and HPV52 infection induced diseases, such as cervical cancer.
The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.
The invention relates to a truncated L1 protein of the Human Papillomavirus Type 18, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.
The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.
The invention relates to a truncated L1 protein of the Human Papillomavirus Type 16, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
A61K 39/00 - Medicinal preparations containing antigens or antibodies
89.
METHOD FOR QUANTITATIVE DETECTION OF ANTI-HBC AND USE THEREOF IN MONITORING DISEASE PROGRESSION OF CHRONIC HEPATITIS B PATIENTS AND PREDICTING THERAPEUTIC EFFECTS
Disclosed in the present invention are an antibodies against hepatitis B core protein (Anti-HBc) quantitative detection method and the uses thereof in monitoring and controlling disease progression of a chronic hepatitis B patient and in predicting therapeutic effect. Anti-HBc are quantitatively detected, so that disease progression of a chronic hepatitis B patient is monitored and controlled, and the therapeutic effect on a chronic hepatitis B patient under anti-hepatitis B virus (HBV) treatment (especially, under treatment based on interferon and under treatment through anti-HBV medicine based on nucleoside or nucleotide analogues) is effectively predicted, thereby guiding the patient to reasonably select medicine.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Described are methods for the preparation of a HPV vaccine composition by, for example (i) adsorbing one or more HPV antigen(s) on a metallic salt and, then (ii) adding a non adsorbed glycolipid based TLR4 ligand to the mixture obtained in (i). Resulting HPV vaccine compositions and uses thereof are also described.
Disclosed is a zinc zoledronate micro-nanoparticle adjuvant, which contains zinc and zoledronic acid and optionally contains a phosphate and aluminum. The preparation method therefor comprises performing mixed precipitation on a soluble salt solution containing zinc ions, zoledronic acid, and sodium hydroxide. The adjuvant can be used to prepare vaccines, etc.
The present invention falls within the technical field of medicine. In particular, the present invention relates to a risedronate zinc micronano-adjuvant which has a slow-release function and is formed by mineralizing the major components, zinc ions and risedronic acid, and the use of same as a vaccine adjuvant. The present invention also relates to a method for preparing the risedronate zinc micronano-adjuvant. The present invention also relates to a chemical composition, a vaccine adjuvant and a vaccine composition containing the risedronate zinc micronano-adjuvant. Furthermore, the present invention relates to the use of the risedronate zinc micronano-adjuvant as a vaccine adjuvant.
